doi: 10.1016/j.exger.2008.02.007 122 ReardonTFAllenDG
Stanley et al
Benefits Beyond Weight Loss: Metabolic and Cardiovascular Health Cardiovascular risk reduction semaglutide reduced major cardiovascular events by 20% in the SELECT trial Blood sugar control significant HbA1c reductions in patients with type 2 diabetes or prediabetes Reduced liver fat growing evidence supports GLP-1 therapy for NAFLD and MASLD Sleep apnea improvement tirzepatide demonstrated 63% reduction in apnea-hypopnea index (2024 NEJM trial) Fatty Liver Disease & GLP-1 Therapy Patients with NAFLD/MASLD may see significant improvement with GLP-1 treatment
This declaration meant that, technically, compounding pharmacies should have stopped producing tirzepatide products
Compounded tirzepatideprescriptions are limited to residents in the following states: AZ, CA, CO, DE, FL, GA, HI, IA, ID, IL, KS, MA, MD, ME, MO, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SD, TN, TX, UT, VA, VT, WA, WI, WV, Washington D.C., WY
(2020) 20:e46